Q linea

Q linea FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Q linea (QLINEA.ST) as of Nov 4, 2026 is 92.98 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 86.45 % — a change of 7.56% (higher).

FCF Conversion

92.98 %

YoY

7.56%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Q linea is 2025 92.98 % . FCF Conversion Rate (FCF/EBITDA) of Q linea was 2024 86.45 % . It decreases by 7.56% higher compared to the previous year.

The Q linea FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2018
96.69 SEK
Jan 1, 2019
99.62 SEK
Jan 1, 2020
113.78 SEK
Jan 1, 2021
114.51 SEK
Jan 1, 2022
97.22 SEK
Jan 1, 2023
103.27 SEK
Jan 1, 2024
86.45 SEK
Jan 1, 2025
92.98 SEK
The Q linea FCF Conversion history
YEARFCF ConversionYoY
92.98 %+7.56%
86.45 %-16.29%
103.27 %+6.22%
97.22 %-15.10%
114.51 %+0.64%
113.78 %+14.21%
99.62 %+3.03%
96.69 %+2.87%
94.00 %+4.88%
89.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Q linea Stock analysis

What does Q linea do? Q-linea AB develops and manufactures in-vitro diagnostic solutions for infectious diseases, focusing on antibiotic susceptibility testing. The company's core product, ASTar, is a fully-automated instrument that provides susceptibility profiles within three to six hours directly from positive blood cultures. This enables early targeted antibiotic administration for sepsis identification in hospital patients, primarily serving hospital laboratories. The firm measures bacteria's antimicrobial susceptibility using its own disposables, which are integral to the ASTar system's operation. Q-linea AB's revenue model is based on selling the ASTar instrument and its associated disposables to hospital laboratories. The company's product is specifically designed for sepsis identification in hospital settings, where rapid and accurate antibiotic susceptibility testing is critical. By providing a faster solution than traditional methods, Q-linea targets hospital labs seeking to improve patient outcomes in sepsis cases. The company operates as a holding company with a focus on developing and manufacturing IVD solutions. Its primary customers are hospital laboratories, which purchase the ASTar system and disposables to streamline their diagnostic processes. The firm's business model centers on the sale of both the instrument and the consumable disposables, creating recurring revenue streams from ongoing disposables usage. Q linea is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Q linea stock

FCF Conversion Rate (FCF/EBITDA) of Q linea is 92.98 % in 2025.

FCF Conversion Rate (FCF/EBITDA) of Q linea changed from 86.45 % to 92.98 %, representing a 7.56% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Q linea since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Q linea with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Q linea

All Key Metrics — Q linea